Challenges and opportunities for In Vivo imaging in oncology

Technology in Cancer Research and Treatment

Volumn 1, Issue 6, 2002, Pages 419-422

  Sullivan, Daniel C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; MATRIX METALLOPROTEINASE INHIBITOR; TRACER;

DIAGNOSTIC IMAGING; FEASIBILITY STUDY; HUMAN; IMAGING; IN VIVO STUDY; ISOTOPE LABELING; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0038335919     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460200100602     Document Type: Review

References (4)

1. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., Gwyther, S. G. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 92, 205-216 (2000).
2. Coussens, L. M., Fingleton, B., Matrisian, L. M. Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science 295, 2387-2392 (2002).
3. Louie, A. L., Hüber, M. M., Ahrens, E. T., Rothbächer, U., Moats, R., Jacobs, R. E., Fraser, S. E., and Meade, T. J. In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnology 18, 321-325 (2000).
4. Weissleder, R., Tung, C., Mahmood, U., and Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnology 17, 375-378 (1999).